Upadacitinib: Mechanism of action, clinical, and translational science by Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung

Get full text

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis by Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed

Get full text

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 by Uta Kiltz, Mitsumasa Kishimoto, Jessica A. Walsh, Percival Sampaio-Barros, Manish Mittal, Christopher D. Saffore, Peter Wung, Fabiana Ganz, Ana Biljan, Denis Poddubnyy

Get full text

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study by Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D. Inman, Hideto Kameda, Yihan Li, Xianwei Bu, Anna Shmagel, Peter Wung, In-Ho Song, Atul Deodhar

Get full text

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study by Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, Liang Chen, Yuanyuan Duan, Jianzhong Liu, Ralph Lippe, Peter Wung

Get full text